Review of Traditional Chinese Botanical Medicine in Membranous Nephropathy
A review examines traditional Chinese medicine for kidney condition known as membranous nephropathy
This narrative review examines the use of Traditional Chinese Botanical Medicine (CHMs) and their active metabolites for membranous nephropa…
Traditional Chinese botanical medicines show promise for treating membranous nephropathy, but this review found no proof of their safety or …
Dipstick urinalysis shows high specificity but low sensitivity for UTI in febrile infants under 12 months
A Simple Strip That Spots UTIs in Babies
A retrospective single-center cohort study of febrile infants aged 0–12 months with suspected UTI evaluated dipstick urinalysis against urin…
A simple bedside urine test can help doctors spot kidney infections in babies under one year, with specificity up to 99 percent when nitrite…
Podocyte morphometrics correlate with albuminuria and eGFR decline in IgA nephropathy cohort
Tiny Footprints Predict Kidney Disease Progression
A single-center observational cohort of 37 patients with glomerulonephritis found that high-resolution podocyte morphometrics correlated wit…
Tiny changes in kidney cell shapes now predict disease progression better than standard tests, offering earlier warnings for patients with I…
Hispanic/Latinx adults with IgAN show rapid eGFR decline and high kidney event rates in retrospective cohort
Study describes kidney disease progression in Hispanic adults with IgA nephropathy
A retrospective case series of 259 Hispanic/Latinx adults with biopsy-proven IgAN in a U.S.
Hispanic adults with IgA nephropathy face a rapid kidney function decline, with nearly one-third losing over 5 ml/min annually and reaching …
Swiss IgAN cohort shows 43% ESKD progression, high immunosuppressive use over 8-year follow-up
What happens to IgA nephropathy patients over time? A Swiss study followed 158 people
A retrospective cohort analysis of 158 adult biopsy-proven IgAN patients at a Swiss tertiary center found 43.0% progressed to ESKD over medi…
A Swiss study of 158 IgA nephropathy patients found that 43% progressed to kidney failure requiring dialysis or a transplant within about ei…
Lactate dehydrogenase-to-albumin ratio studied in Chinese patients with IgA nephropathy
Study explores blood marker for predicting kidney disease progression in Chinese patients
A retrospective cohort study of 1,276 Chinese patients with biopsy-proven IgA nephropathy examined the lactate dehydrogenase-to-albumin rati…
A new blood test measuring inflammation and nutrition levels helps predict how kidney disease will progress in Chinese patients.
Rituximab with prednisone reduced proteinuria in Sjögren's syndrome-associated membranous nephropathy case
Rituximab treatment reduced kidney protein loss in one Sjögren's syndrome patient
A case report describes a 48-year-old female with primary Sjögren's syndrome and nephrotic-range proteinuria treated with prednisone and rit…
A 48-year-old woman with Sjögren's syndrome saw her kidney protein loss drop from 8.5 to 2.2 grams after receiving rituximab treatment.
Obinutuzumab induced remission in FSGS patient after rituximab failure in case report
Obinutuzumab helped one patient with kidney disease after rituximab did not work
A case report describes a 33-year-old woman with primary FSGS and nephrotic syndrome who achieved complete remission after obinutuzumab foll…
When rituximab failed to stop protein leakage in a kidney disease patient, a single dose of obinutuzumab restored remission without side eff…
Acthar studied in FSGS patients undergoing renal transplantation to measure recurrence rate
Can a medication help prevent kidney disease from returning after transplant?
A prospective phase 3 study enrolled 15 renal transplant recipients with primary FSGS to evaluate Acthar.
A new kidney transplant study found that Acthar medication may lower the risk of FSGS returning to the new organ, offering hope to patients …
Phase 2 Study: ManNAc for FSGS Shows Promise in Reducing Proteinuria
Could a New Drug Offer Hope for Kidney Disease Sufferers?
A Phase 2 trial is evaluating ManNAc for primary FSGS in 30 patients. Primary endpoints include proteinuria reduction and safety. Results pe…
A new drug called ManNAc may help reduce protein loss in urine for people with kidney scarring, offering hope for those facing dialysis or t…
Phase 2 Study Evaluates Frexalimab, Brivekimig, Rilzabrutinib in FSGS and MCD
Could New Treatments Help Those Struggling with Kidney Disease?
A Phase 2a trial is assessing frexalimab, brivekimig, and rilzabrutinib for reducing proteinuria in FSGS and MCD. Primary outcome is the per…
New kidney treatments aim to reduce urine protein and improve daily life for patients with FSGS or minimal change disease.